Dasatinib monohydrate

CAS:863127-77-9
IHS
USDMF No. 23763, USFDA  Approved, Stability Studies In Zone IVB
1
1
药丸3
药丸3
实验
实验
药丸2
药丸2
人像
人像

PRODUCTS

Back

Technical Data

 

M. Wt 506.02
Formula C22H28ClN7O3S
CAS Number 863127-77-9
PubChem ID 11540687
InChI Key XHXFZZNHDVTMLI-UHFFFAOYSA-N
Smiles O.CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Documents USFDA Approved, USDMF available, Stability Studies In Zone IVB.

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

 

Description

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of , are BCRABL, SRC, Ephrins and GFR.

 

Synonyms

 

Dasatinib, Dasatinib hydrate, dasatinib.H2O, Dasatinib (monohydrate), N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide hydrate, dasatinib-monohydrate

 

Disclaimer

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)

Dasatinibmonohydrate